27 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 BIOTECH STARTUPS accelerated review pathways, and real-time regulatory guidance. Investors are encouraged by these efforts, fuelling early-stage biotech firms tackling unmet medical needs. This synergy between regulators and venture capital is driving faster innovation and patient access. “[We support] policies that streamline the regulatory approval process at the FDA, particularly for novel technologies, and the reimbursement process at the Center for Medicare and Medicaid (CMS),” said The National Venture Capital Association’s (NVCA) Ashlyn Roberts. “Process improvements are critical to encouraging investors to take the long-term risk of pursuing new medical innovations.” Roberts, who is VP of Government Affairs at the NVCA, also expressed support of a federal commitment to robust basic research funding and federal technology transfer programs so promising developments can be commercialised and foster job creation. The drive towards faster innovation is levelling up the playing field not just geographically but within the players in the biotech space. Reuters recently reported on a conference in India in which companies like Amgen and Parexel showcased how AI can reduce trial times, with Parexel demonstrating a model that speeds up drug safety reports by 30-45 minutes. Industry experts believe that AI-driven drug discovery could cut down the process from over a decade to just a few years, essentially allowing startups to compete with established pharmaceutical companies. From vision to reality: Startups spearheading innovation charge Generate:Biomedicines Massachusetts-based Generate:Biomedicines is making waves in the drug discovery arena with its use of AI in designing novel protein-based therapeutics across oncology, immunology, and infectious diseases. Backed by $370 million in Series B funding, the startup’s AI-driven approach enables faster, more precise drug development. “We are at the forefront of a biological revolution,” said the company’s CEO Mike Nally. “Generative AI is enabling us to tackle some of the toughest challenges in drug discovery, from historically undruggable and hard-to-drug targets to optimising molecules with unprecedented precision. As more of our programs advance into the clinic, we’re demonstrating how our platform is creating differentiated medicines — while at the same time transforming the very process by which they are made.” The company’s ‘Generate Platform’ integrates machine learning, high-throughput experimentation, and at-scale structural determination to enable programmable biology. It’s capabilities address therapeutic areas that include immunology & inflammation and infectious diseases, where its first AI-generated viral neutralising antibody targeting SARS-CoV‑2, achieved positive Phase 1 results. Constructive Bio UK-based Constructive Bio are a company leading the way in synthetic biology by focusing on whole genome writing and engineered translation to create programmable biomolecules for next-generation therapeutics. These therapeutics are the result of more efficient methods to manufacture therapeutic peptides and proteins, such as semaglutide analogues used in diabetes treatment. “What we’re particularly excited about is the ability to convert conventional chemical-based synthesis into a process which is dictated by biology,” CEO Ola Wlodek explained to Benchling, one of Constructive Bio’s partners. “Rather than using harmful solvents in large quantities as with chemical synthesis, Constructive can engineer cells to directly synthesise the target molecule with techniques that are readily scaled and built on decades of innovation.” Already recognised on this year’s Sunday Times 100 Tech, Constructive Bio announced back in September 2024 that it has secured $58 million in the first close of its Series A financing, bringing the total amount raised by the company to date to $75 million. Purespring Therapeutics Purespring Therapeutics stands out as a pioneer in gene therapy manufacturing and its potential to transform treatments for chronic kidney diseases. Spunout from the University of Bristol in the UK, Purespring Therapeutics, came to prominence In October 2024, where the company secured £80 million ($102 million) in an oversubscribed Series B financing round.
RkJQdWJsaXNoZXIy MjY2OTA4MA==